Document is current

Article History

Received: 2 November 2020

Accepted: 27 May 2021

First Online: 25 August 2021

Competing interests

: R.B-S. has served as an advisor/consultant to Eli Lilly, Merck Sharp and Dohme, Roche, and Zodiac and has received honoraria from Bard Access, Bristol-Myers Squib, Libbs, Eli Lilly, Novartis, Pfizer, Roche, and travel, accommodations, or expenses from Roche and Daiichi-Sankyo. D.D. is on the Advisory Board for Oncology Analytics, Inc, and consults for Novartis. E.A.M. reports research support for lab from Glaxo Smithkline; honoraria from Physician Education Resource; compensated service on Scientific Advisory Boards for AstraZeneca, Exact Sciences (formerly Genomic Health), Merck, Peregrine Pharmaceuticals, Roche/Genentech, Sellas Lifesciences, TapImmune Inc; uncompensated service on Steering Committees for BMS, Lilly, Roche/Genentech; clinical trial funding (paid to institution, MD Anderson) from AstraZeneca, EMD Serono, Galena Biopharma, Roche/Genentech; clinical trial funding (paid to institution, DFCI) from Roche/Genentech (via SU2C grant); and non-financial interests, non-remunerated activities: Board of Directors for the American Society of Clinical Oncology; and Scientific Advisor for Susan G Komen for the Cure Foundation. E.V.A. serves as a consultant/advisor to Tango Therapeutics, Invitae, Genome Medical, Dynamo, Foresite Capital, and Illumina; holds research support from Novartis and Bristol-Myers Squibb; and holds equity in Synapse, Genome Medical, Tango, and Microsoft Corp. D.G.D. received consultant fees from Bayer Pharmaceuticals, Simcere Pharmaceuticals, Surface Oncology and Bristol-Myers Squibb and research grants from Bayer Pharmaceuticals, Exelixis Pharmaceuticals and Bristol-Myers Squibb. S.M.T. receives institutional research funding from Novartis, Genentech, Eli Lilly, Pfizer, Merck, Exelixis, Eisai, Bristol Meyers Squibb, AstraZeneca, Cyclacel, Immunomedics, Odonate, Sanofi, and Nektar. S.M.T. has served as an advisor/consultant to Novartis, Eli Lilly, Pfizer, Merck, AstraZeneca, Eisai, Puma, Genentech, Immunomedics, Nektar, Paxman, Athenex, Oncopep, Daiichi-Sankyo, G1 Therapeutics, Silverback Therapeutics, Kyowa Kirin Pharmaceuticals, AbbVie, Sanofi, Seattle Genetics, Celldex, Bristol-Myers Squibb and Nanostring. The remaining authors declare no competing interests.